Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
Joint Authors
Loeser, Heike
Kraemer, Max
Gebauer, Florian
Bruns, Christiane
Schröder, Wolfgang
Zander, Thomas
Alakus, Hakan
Hoelscher, Arnulf
Buettner, Reinhard
Lohneis, Philipp
Quaas, Alexander
Source
Journal of Immunology Research
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-09-22
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Background.
Indoleamine 2,3-dioxygenase (IDO) is an interferon-inducible immune checkpoint expressed on tumor-infiltrating lymphocytes (TILs).
IDO is known as a poor prognostic marker in esophageal squamous cell cancer, while a positive effect was shown for breast cancer.
A comprehensive analysis of IDO expression in a well-defined cohort of esophageal adenocarcinoma (EAC) is missing.
Methods.
We analyzed 551 patients with EAC using single-protein and multiplex immunohistochemistry as well as mRNA in situ technology for the expression and distribution of IDO on subtypes of TILs (INF-γ mRNA and CD4- and CD8-positive T lymphocytes).
Results.
IDO expression on TILs was seen in up to 59.6% of tumors, and expression on tumor cells was seen in 9.2%.
We found a strong positive correlation of IDO-positive TILs, CD3-positive T lymphocytes, and INF-γ mRNA-producing TILs in the tumor microenvironment of EACs showing significantly better overall survival (47.7 vs.
22.7 months, p<0.001) with emphasis on early tumor stages (pT1/2: 142.1 vs.
37.1 months, p<0.001).
In multivariate analysis, IDO is identified as an independent prognostic marker.
Conclusions.
Our study emphasizes the importance of immunomodulation in EAC marking IDO as a potential biomarker.
Beyond this, IDO might indicate a subgroup of EAC with an explicit survival benefit.
American Psychological Association (APA)
Loeser, Heike& Kraemer, Max& Gebauer, Florian& Bruns, Christiane& Schröder, Wolfgang& Zander, Thomas…[et al.]. 2020. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma. Journal of Immunology Research،Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1187087
Modern Language Association (MLA)
Loeser, Heike…[et al.]. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma. Journal of Immunology Research No. 2020 (2020), pp.1-10.
https://search.emarefa.net/detail/BIM-1187087
American Medical Association (AMA)
Loeser, Heike& Kraemer, Max& Gebauer, Florian& Bruns, Christiane& Schröder, Wolfgang& Zander, Thomas…[et al.]. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma. Journal of Immunology Research. 2020. Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1187087
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1187087